KCS rTMS Therapy System (Transcranial Magnetic Stimulator) (MetaStim 100, MetaStim 100A)
Fidelity BioPharma Co. · Decision date Sep 6, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 6, 2026 for K260396, a traditional 510(k) from Fidelity BioPharma Co. of New Haven, Connecticut, for the KCS rTMS Therapy System (Transcranial Magnetic Stimulator), models MetaStim 100 and MetaStim 100A. The device is a Class II repetitive transcranial magnetic stimulation system under 21 CFR 882.5805, product code OBP, in the Neurology panel. Clearance is not PMA approval.
The submission describes a host with master control unit, power supply, software and cooling unit, plus an MD-60 figure-of-eight stimulation coil; motor evoked potential, coil stand and MetaStim software are optional. The sponsor states the primary predicate is Ultimate rTMS/Yingchi rTMS (K230735), with Neurosoft TMS/CloudTMS (K173441) as a reference device, and reports the same intended use, product code and regulation. The summary states differences raise no new safety or effectiveness questions. Coil dimensions differ, marked "Similar Note 1," but the note's content is not in the provided excerpts.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Sep 6, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260396
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Fidelity BioPharma Co.
- Product code
- OBP
- Decision code
- SESE
- Decision date
- Sep 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transcranial Magnetic Stimulator.
- Applicant
- Fidelity BioPharma Co.
- Product code
- OBP
- FDA device class
- 2
FDA decision timeline
K260396 received
Application receipt date recorded by FDA.
K260396 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fidelity BioPharma Co.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- New Haven, CT
Sources and methodology
- Original FDA record: K260396
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records